SEARCH:   Advanced

Blood, 14 May 2009, Vol. 113, No. 20, pp. 4918-4921. Prepublished online as a Blood First Edition Paper on March 3, 2009; DOI 10.1182/blood-2008-08-174110. This Article Full Text Full Text (PDF) Supplemental Methods, Tables, and Figures All Versions of this Article: blood-2008-08-174110v1 113/20/4918    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Google Scholar Articles by Novak, U. Articles by Bertoni, F. PubMed PubMed Citation Articles by Novak, U. Articles by Bertoni, F. Related Collections Lymphoid Neoplasia Brief Reports Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  LYMPHOID NEOPLASIA Brief Report The NF-B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas Urban Novak1, Andrea Rinaldi2, Ivo Kwee2,3, Subhadra V. Nandula1, Paola M. V. Rancoita2,3, Mara Compagno1, Michaela Cerri4, Davide Rossi4, Vundavalli V. Murty1, Emanuele Zucca2, Gianluca Gaidano4, Riccardo Dalla-Favera1, Laura Pasqualucci1, Govind Bhagat1,*, and Francesco Bertoni2,* 1 Institute for Cancer Genetics, Departments of Pathology and Genetics & Development, and the Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY; 2 Laboratory of Experimental Oncology and Lymphoma Unit, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland; 3 Istituto Dalle Molle di Studi sull'Intelligenza Artificiale, Manno, Switzerland; and 4 Division of Hematology, Department of Clinical and Experimental Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy Unique and shared cytogenetic abnormalities have been documented for marginal zone lymphomas (MZLs) arising at different sites. Recently, homozygous deletions of the chromosomal band 6q23, involving the tumor necrosis factor alpha–induced protein 3 (TNFAIP3, A20) gene, a negative regulator of NF-B, were described in ocular adnexal MZL, suggesting a role for A20 as a tumor suppressor in this disease. Here, we investigated inactivation of A20 by DNA mutations or deletions in a panel of extranodal MZL (EMZL), nodal MZL (NMZL), and splenic MZL (SMZL). Inactivating mutations encoding truncated A20 proteins were identified in 6 (19%) of 32 MZLs, including 2 (18%) of 11 EMZLs, 3 (33%) of 9 NMZLs, and 1 (8%) of 12 SMZLs. Two additional unmutated nonsplenic MZLs also showed monoallelic or biallelic A20 deletions by fluorescent in situ hybridization (FISH) and/or SNP-arrays. Thus, A20 inactivation by either somatic mutation and/or deletion represents a common genetic aberration across all MZL subtypes, which may contribute to lymphomagenesis by inducing constitutive NF-B activation. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: K. Honma, S. Tsuzuki, M. Nakagawa, H. Tagawa, S. Nakamura, Y. Morishima, and M. Seto TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas Blood, September 17, 2009; 114(12): 2467 - 2475. [Abstract] [Full Text] [PDF] R. Schmitz, M.-L. Hansmann, V. Bohle, J. I. Martin-Subero, S. Hartmann, G. Mechtersheimer, W. Klapper, I. Vater, M. Giefing, S. Gesk, et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma J. Exp. Med., May 11, 2009; 206(5): 981 - 989. [Abstract] [Full Text] [PDF] B. A. Malynn and A. Ma A20 takes on tumors: tumor suppression by an ubiquitin-editing enzyme J. Exp. Med., May 11, 2009; 206(5): 977 - 980. [Abstract] [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020